Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial Read More »
